181 related articles for article (PubMed ID: 35280727)
21. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
Medicine (Baltimore); 2018 Aug; 97(33):e11936. PubMed ID: 30113497
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
Qian X; Li Z; Ruan G; Tu C; Ding W
Breast Cancer Res Treat; 2020 Jan; 179(2):275-285. PubMed ID: 31606823
[TBL] [Abstract][Full Text] [Related]
24. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer.
Stenehjem DD; Tran D; Nkrumah MA; Gupta S
Onco Targets Ther; 2018; 11():5973-5989. PubMed ID: 30275703
[TBL] [Abstract][Full Text] [Related]
25. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma.
Ibrahiem AT; Eladl E; Toraih EA; Fawzy MS; Abdelwahab K; Elnaghi K; Emarah Z; Shaalan AAM; Ehab Z; Soliman NA
Diagnostics (Basel); 2023 Jan; 13(2):. PubMed ID: 36673047
[TBL] [Abstract][Full Text] [Related]
27. Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.
Carretero-González A; Lora D; Ghanem I; Zugazagoitia J; Castellano D; Sepúlveda JM; López-Martin JA; Paz-Ares L; de Velasco G
Oncotarget; 2018 Feb; 9(9):8706-8715. PubMed ID: 29492229
[TBL] [Abstract][Full Text] [Related]
28. Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis.
Yang W; Men P; Xue H; Jiang M; Luo Q
Front Oncol; 2020; 10():197. PubMed ID: 32211312
[No Abstract] [Full Text] [Related]
29. Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta-analysis.
Malaty MM; Amarasekera AT; Li C; Scherrer-Crosbie M; Tan TC
Eur J Clin Invest; 2022 Dec; 52(12):e13831. PubMed ID: 35788986
[TBL] [Abstract][Full Text] [Related]
30. Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
Tzeng A; Diaz-Montero CM; Rayman PA; Kim JS; Pavicic PG; Finke JH; Barata PC; Lamenza M; Devonshire S; Schach K; Emamekhoo H; Ernstoff MS; Hoimes CJ; Rini BI; Garcia JA; Gilligan TD; Ornstein MC; Grivas P
Target Oncol; 2018 Oct; 13(5):599-609. PubMed ID: 30267200
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review.
Ma X; Zhang Y; Wang S; Wei H; Yu J
J Cancer; 2021; 12(5):1318-1333. PubMed ID: 33531977
[No Abstract] [Full Text] [Related]
32. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
[TBL] [Abstract][Full Text] [Related]
33. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy.
Weidhaas J; Marco N; Scheffler AW; Kalbasi A; Wilenius K; Rietdorf E; Gill J; Heilig M; Desler C; Chin RK; Kaprealian T; McCloskey S; Raldow A; Raja NP; Kesari S; Carrillo J; Drakaki A; Scholz M; Telesca D
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35115362
[TBL] [Abstract][Full Text] [Related]
34. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Luo W; Wang Z; Tian P; Li W
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
[TBL] [Abstract][Full Text] [Related]
35. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
[TBL] [Abstract][Full Text] [Related]
36. Programmed cell death 1 and programmed cell death ligand 1 expression in invasive breast carcinoma using CAL10 and NAT105 immunostaining.
Durak Ö; Bozkurt KK; Çiriş İM; Kocer M; Eroğlu HE
Biotech Histochem; 2023 Feb; 98(2):147-154. PubMed ID: 36281760
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
38. Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment.
Wang YL; Gong Y; Lv Z; Li L; Yuan Y
J Cancer; 2021; 12(6):1698-1707. PubMed ID: 33613757
[No Abstract] [Full Text] [Related]
39. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
Huo X; Shen G; Liu Z; Liang Y; Li J; Zhao F; Ren D; Zhao J
Crit Rev Oncol Hematol; 2021 Dec; 168():103530. PubMed ID: 34801695
[TBL] [Abstract][Full Text] [Related]
40. Extended Adjuvant Therapy With Aromatase Inhibitors for Early Breast Cancer: A Meta-analysis of Randomized Controlled Trials.
Xu L; Zhang Z; Xiang Q; Liu Q; Duan X; Liu Y; Cui Y
Clin Breast Cancer; 2019 Oct; 19(5):e578-e588. PubMed ID: 31257015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
